DFN 02

Drug Profile

DFN 02

Alternative Names: DFN-02; DFP 02

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Dr Reddys Laboratories
  • Class Antimigraines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 04 Apr 2017 Phase-III development for Migraine is ongoing in USA
  • 11 Jul 2016 Dr Reddy's Laboratories initiates a phase II trial in Migraine in USA (NCT02856802)
  • 01 Mar 2016 Dr. Reddy's Laboratories completes a phase III trial in Migraine in USA (unspecified route) (NCT02279082)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top